Literature DB >> 17053462

How I manage donors and patients with a weak D phenotype.

Willy A Flegel1.   

Abstract

PURPOSE OF REVIEW: Since the adoption of molecular blood-group typing, the considerable heterogeneity of the serologic entities weak D and DEL at the molecular level has come to light. I offer an approach to the management of donors and patients expressing D antigen weakly and carrying any of the various molecular types of weak D and DEL. RECENT
FINDINGS: More than 50 distinct weak D alleles have been described. An internet-based survey of anti-D immunizations occurring in D-positive transfusion recipients reveals that no allo-anti-D has been observed in patients carrying prevalent weak D types. Allo-immunizations are documented for weak D types 4.2 (also known as DAR), 11 and 15. Anti-D immunizations have been reported in D-negative persons transfused with weak D and DEL red blood cells.
SUMMARY: Patients carrying any of the prevalent weak D types 1, 2, 3 or 4.1 are not prone to allo-anti-D immunization and may safely be transfused with D-positive red blood cells. Pregnant women with these weak D types need not receive RhIg. We should pay attention to weak D- or DEL-positive blood units that are labelled D-negative. The clinical benefit of removing DEL blood units from our supply of D-negative red blood cell units should be determined.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053462     DOI: 10.1097/01.moh.0000245694.70135.c3

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  31 in total

Review 1.  Molecular genetics and clinical applications for RH.

Authors:  Willy A Flegel
Journal:  Transfus Apher Sci       Date:  2011-01-28       Impact factor: 1.764

2.  RHD allelic identification among D-Brazilian blood donors as a routine test using pools of DNA.

Authors:  Mariza Mota; M Dezan; M C Valgueiro; A M Sakashita; J M Kutner; L Castilho
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

3.  A mythical beast. Increased attention highlights the hidden wonders of chimeras.

Authors:  Howard Wolinsky
Journal:  EMBO Rep       Date:  2007-03       Impact factor: 8.807

4.  The genetics of the Rhesus blood group system.

Authors:  Willy A Flegel
Journal:  Blood Transfus       Date:  2007-04       Impact factor: 3.443

5.  Weak D in the Tunisian population.

Authors:  Mouna Ouchari; Houda Romdhane; Taher Chakroun; Saida Abdelkefi; Batoul Houissa; Slama Hmida; Saloua Jemni Yacoub
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

6.  Molecular immunohaematology round table discussions at the AABB Annual Meeting, Denver 2013.

Authors:  Willy A Flegel; Lilian Castilho; Meghan Delaney; Ellen B Klapper; Joann M Moulds; France Noizat-Pirenne; Nadine Shehata; Gary Stack; Christopher A Tormey; Franz F Wagner; Dan A Waxman; Christof Weinstock; Silvano Wendel; Gregory A Denomme
Journal:  Blood Transfus       Date:  2014-12-02       Impact factor: 3.443

7.  Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn.

Authors:  Francesco Bennardello; Serelina Coluzzi; Giuseppe Curciarello; Tullia Todros; Stefania Villa
Journal:  Blood Transfus       Date:  2015-01       Impact factor: 3.443

8.  A proposal for a rational transfusion strategy in patients of European and North African descent with weak D type 4.0 and 4.1 phenotypes.

Authors:  Willy A Flegel; Thierry Peyrard; Jacques Chiaroni; Christophe Tournamille; Déborah Jamet; France Pirenne
Journal:  Blood Transfus       Date:  2018-05-03       Impact factor: 3.443

Review 9.  Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype.

Authors:  S Gerald Sandler; Leonard N Chen; Willy A Flegel
Journal:  Br J Haematol       Date:  2017-05-16       Impact factor: 6.998

10.  Distribution of Rhesus blood group antigens and weak D alleles in the population of Albania.

Authors:  Merita Xhetani; Irena Seferi; Claude Férec; Grigor Zoraqi; Yann Fichou
Journal:  Blood Transfus       Date:  2014-06-12       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.